People | February 23, 2022
Sumitomo Dainippon Pharma Oncology appoints Jatin J. Shah as Chief Medical Officer
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
Subscribe To Our Newsletter & Stay Updated
